Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07511062
PHASE1

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML

Sponsor: Northside Hospital, Inc.

View on ClinicalTrials.gov

Summary

Axatilimab combined with Decitabine/Venetoclax for the treatment of TP53-mutated/deleted AML patients

Official title: Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated/Deleted AML Patients

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2026-08-01

Completion Date

2030-08-01

Last Updated

2026-04-06

Healthy Volunteers

No

Interventions

DRUG

Decitabine

20mg/m2/d x5 days (induction \& consolidation)

DRUG

Venetoclax

400mg/d x14 days (induction); 400mg/d x7 days (consolidation)

DRUG

Axatilimab

Dose escalation, given on Days 1 and 15 of each cycle

Locations (1)

Northside Hospital, Inc.

Atlanta, Georgia, United States